LungLife AI, INC Director share purchases (1228F)
November 03 2022 - 3:00AM
UK Regulatory
TIDMLLAI
RNS Number : 1228F
LungLife AI, INC
03 November 2022
LungLife AI, Inc.
(the "Company" or "LungLife")
Director share purchases
LungLife AI (AIM: LLAI), a developer of clinical diagnostic
solutions for lung cancer, announces that it has received
notification of the following transactions in the Company's common
shares of US $0.0001 each ("Common Shares") undertaken by
directors.
On 2 November 2022, Paul Pagano, Chief Executive Officer,
purchased 5,000 Common Shares at a price of 130 pence per share.
Following this purchase, Paul Pagano now holds 5,000 Common Shares,
representing approximately 0.02% of the outstanding share capital
of the Company.
In addition, on 2 November 2022, David Anderson, Chief Financial
Officer, purchased 5,000 Common Shares at a price of 130 pence per
share. Following this purchase, David Anderson now holds 5,000
Common Shares, representing approximately 0.02% of the outstanding
share capital of the Company.
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com
Paul Pagano, CEO Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser Tel: +44 (0)20 7597 5970
& Broker)
Daniel Adams / Virginia Bull / Cameron
MacRitchie
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
Paul McManus / Alice Woodings / Phillip Mob: 07980 541 893 / 07407 804 654 /
Marriage 07867 984 082
About LungLife AI
LungLife AI is a developer of clinical diagnostic solutions
designed to make a significant impact in the early detection of
lung cancer, the deadliest cancer globally. Using a minimally
invasive blood draw, the Company's LungLB(R) test is designed to
deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit
www.lunglifeai.com
Notification of transactions by Directors, Persons Discharging
Managerial Responsibilities ("PDMRs") and persons closely
associated with them.
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Paul Pagano
--------------------------------- -------------------------------------
2. Reason for the Notification
------------------------------------------------------------------------
a) Position/status Chief E xecutive Officer
--------------------------------- -------------------------------------
b) Initial notification/amendment Initial notification
--------------------------------- -------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------
a) Name LungLife AI, Inc
--------------------------------- -------------------------------------
b) LEI 549300VBVDIF0Y3OVI38
--------------------------------- -------------------------------------
4. Details of the transaction(s):section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv)each place where transactions have been
conducted
------------------------------------------------------------------------
a) Description of the Financial Common shares of $0.0001 each in the
instrument, type of instrument, capital of the Company
identification code
ISIN: USU5500L1045
--------------------------------- -------------------------------------
b) Nature of the Transaction Purchase of Common Shares
--------------------------------- -------------------------------------
c) Price(s) and volume(s) Price Volume
130 pence 5,000
-------
--------------------------------- -------------------------------------
d) Aggregated information As above
* Aggregated volume
* Price
--------------------------------- -------------------------------------
e) Date of the transaction 2/11/2022
--------------------------------- -------------------------------------
f) Place of the transaction London Stock Exchange
--------------------------------- -------------------------------------
Notification of transactions by Directors, Persons Discharging
Managerial Responsibilities ("PDMRs") and persons closely
associated with them.
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name David Anderson
--------------------------------- -------------------------------------
2. Reason for the Notification
------------------------------------------------------------------------
a) Position/status Chief Financial Officer
--------------------------------- -------------------------------------
b) Initial notification/amendment Initial notification
--------------------------------- -------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------
a) Name LungLife AI, Inc
--------------------------------- -------------------------------------
b) LEI 549300VBVDIF0Y3OVI38
--------------------------------- -------------------------------------
4. Details of the transaction(s):section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv)each place where transactions have been
conducted
------------------------------------------------------------------------
a) Description of the Financial Common shares of $0.0001 each in the
instrument, type of instrument, capital of the Company
identification code
ISIN: USU5500L1045
--------------------------------- -------------------------------------
b) Nature of the Transaction Purchase of Common Shares
--------------------------------- -------------------------------------
c) Price(s) and volume(s) Price Volume
130 pence 5,000
-------
--------------------------------- -------------------------------------
d) Aggregated information As above
* Aggregated volume
* Price
--------------------------------- -------------------------------------
e) Date of the transaction 2/11/2022
--------------------------------- -------------------------------------
f) Place of the transaction London Stock Exchange
--------------------------------- -------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBTBFTMTTMBMT
(END) Dow Jones Newswires
November 03, 2022 03:00 ET (07:00 GMT)
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From May 2024 to Jun 2024
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From Jun 2023 to Jun 2024
